• Twist Bioscience recently announced the launch of its customizable Twist Oncology DNA Comprehensive Genomic Profiling (CGP) Panel, designed to enable identification of genomic alterations across a broad range of tumors and support targeted therapy development in oncology research.
• This product expands Twist’s reach into comprehensive tumor profiling with coverage of 562 genes, targeting researchers in clinical labs, academia, and biopharma, and is offered alongside integrated analytics solutions for an end-to-end research workflow.
• We’ll now examine how the release of Twist’s customizable CGP Panel could expand its presence in the oncology research solutions market.

The end of cancer? These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.

Twist Bioscience Investment Narrative Recap

To be a shareholder in Twist Bioscience, you need confidence in its ability to drive revenue through high-impact innovations in genomics and synthetic biology, while overcoming persistent unprofitability and the risks of customer concentration. The launch of the customizable Twist Oncology DNA CGP Panel is a clear example of the company executing on product expansion, supporting short-term growth potential, but it does not materially lessen the immediate challenges related to recurring losses and the pressure to achieve financial breakeven.

Of the recent company announcements, the August 19 launch of the Twist Oncology DNA Comprehensive Genomic Profiling Panel stands out for its alignment with ongoing efforts to broaden Twist’s market reach and boost relevance in the oncology research space. By positioning this product alongside its analytics partnerships, Twist is building a more integrated offering that could help differentiate it amidst margin and revenue volatility risks tied to larger, concentrated customers.

However, investors should also be aware that despite impressive product news, the underlying risk of reliance on a handful of large NGS customers remains a critical...

Twist Bioscience's narrative projects $575.2 million in revenue and $105.5 million in earnings by 2028. This requires 16.7% yearly revenue growth and a $190.7 million increase in earnings from the current $-85.2 million.

Uncover how Twist Bioscience's forecasts yield a $40.00 fair value, a 48% upside to its current price.

Exploring Other Perspectives

Three members of the Simply Wall St Community place Twist Bioscience’s fair value between US$35.47 and US$99.11, reflecting wide-ranging individual outlooks. While top-line drivers like new oncology solutions surface, beware that concentrated NGS customer exposure can strongly influence Twist’s revenue stability and future market position, explore more community viewpoints to inform your own perspective.

Explore 3 other fair value estimates on Twist Bioscience - why the stock might be worth just $35.47!

Build Your Own Twist Bioscience Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Twist Bioscience research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Twist Bioscience research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Twist Bioscience's overall financial health at a glance.

Seeking Other Investments?

The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

• We've found 19 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.
• These 14 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.
• This technology could replace computers: discover 23 stocks that are working to make quantum computing a reality.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.